Previous close | 9.29 |
Open | 10.96 |
Bid | 9.40 |
Ask | 11.10 |
Strike | 35.00 |
Expiry date | 2024-12-20 |
Day's range | 10.96 - 11.11 |
Contract range | N/A |
Volume | |
Open interest | 30 |
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 13% in the last...
PASADENA, Calif., June 25, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-2 s
PASADENA, Calif., June 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.